Testing a patient for strep at the pharmacy counter is only half the workflow — the other half is whether you can legally prescribe treatment based on that result without routing the patient back to a physician first. That second half is where “test-and-treat” authority varies enormously by state, and it’s the piece that actually determines whether the service is worth building.
What test-and-treat actually means
Test-and-treat programs let a pharmacist administer a point-of-care test (rapid flu, strep, COVID-19, and in some states RSV or UTI panels) and then, based on the result, initiate treatment — typically an antiviral or antibiotic — under a legal authority that doesn’t require a separate physician visit or prescription. It’s the combination of testing plus prescribing authority that makes it “test-and-treat” rather than just point-of-care testing, which many more states allow without the prescribing piece attached. For the testing side alone, see our companion guide on point-of-care testing authority by state.
The three legal pathways states use
States authorize test-and-treat through different legal mechanisms, and the mechanism matters because it determines how much prescriber involvement is still required:
1. Statewide protocol or standing order — The state health department or board of pharmacy issues a standing protocol that any licensed, appropriately trained pharmacist can practice under, without needing an individual agreement with a specific physician. This is the broadest model — it scales because it doesn’t require a one-to-one relationship with a supervising prescriber.
2. Collaborative practice agreement (CPA) — The pharmacist practices test-and-treat under a CPA with a specific collaborating physician, which typically has to specify the conditions covered, the testing and treatment protocol, and often requires physician notification within a defined window after treatment. This model works but doesn’t scale as easily since it depends on securing and maintaining physician relationships. See our full breakdown of collaborative practice agreements by state for how these are structured generally.
3. Statutory prescriptive authority — A smaller number of states have amended pharmacy practice acts to grant pharmacists direct, statutory authority to test and treat for specific enumerated conditions, without needing either a standing order or an individual CPA. This is the most autonomous model but currently the least common.
Many states use a hybrid — a statewide standing order for flu and strep during declared public health emergencies or specific windows, with CPAs as the fallback mechanism outside of those periods.
Which conditions are typically covered
Test-and-treat authority, where it exists, most commonly covers:
- Influenza A/B — usually the most broadly authorized condition, often bundled with antiviral prescribing (oseltamivir) within the CDC-recommended treatment window
- Group A Streptococcal pharyngitis (strep throat) — rapid antigen test plus antibiotic prescribing
- COVID-19 — many states added COVID test-and-treat authority (including Paxlovid prescribing under EUA-related state actions) during and after the pandemic; the durability of that authority varies as emergency orders have expired in some states
- Urinary tract infections — a smaller but growing number of states allow pharmacist test-and-treat for uncomplicated UTIs in adult women, sometimes via symptom-based protocol rather than an in-pharmacy test
Decision path for building a test-and-treat program
Training and certification requirements
Even where the legal authority exists, most states require specific training before a pharmacist can practice test-and-treat — commonly CLIA waiver training for the point-of-care testing device itself, plus a certificate program covering the specific disease states (flu/strep certificate programs are widely available through ACPE-accredited continuing education providers). Some states also require the pharmacy location itself to hold a CLIA certificate of waiver, which is a facility-level requirement separate from the pharmacist’s individual training.
What varies most by state
- Which conditions are covered (nearly universal for flu/strep; much more variable for UTI and COVID)
- Whether a CPA is required or a standing order suffices
- Physician notification timing and format requirements under CPA models
- Minimum patient age (some states exclude pediatric patients from pharmacist test-and-treat)
- Required documentation and reporting back to the patient’s primary care provider
Given how much this varies and how frequently states are actively expanding pharmacist prescriptive authority, confirm your specific state’s current test-and-treat framework with your board of pharmacy before building or advertising the service — a rule that applied last renewal cycle may have already changed.
Track scope-of-practice changes as they happen
RxByState tracks test-and-treat authority, point-of-care testing rules, and collaborative practice requirements for every state, updated as boards change them. Start a free 14-day trial →